Fukuda Denshi Co., Ltd. (FKDSF) fair value: what the stock is really worth
As of Sep 25, 2026: fair value of Fukuda Denshi Co., Ltd. $72.81, price $42.55, upside +71.1%, quality 68 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Fukuda Denshi Co., Ltd. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
Fukuda Denshi Co., Ltd. engages in the manufacture and sale of medical instruments in Japan and internationally.
Show more
Fukuda Denshi Co., Ltd. engages in the manufacture and sale of medical instruments in Japan and internationally. The company offers resting electrocardiograph and stress test products; patient monitoring systems, including central and bedside monitors, transmitters, and central viewer workstations; and vascular screening systems, such as data management software. Fukuda Denshi Co., Ltd. was founded in 1939 and is based in Tokyo, Japan.
Stock analysis
Fukuda Denshi Co., Ltd. (FKDSF) currently trades at $42.55, while our model-based Fair Value estimate is $72.81, implying the stock looks roughly 41.6% undervalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of $97.38 per share, and 16 of the 24 models we run sit above the $42.55 price.
Bear case: the Dividend Discount group reads lowest at $11.35, and 8 of the 24 models stay below the price. Evidence for this calculation is medium.
Scenario range: $50.97 (bear) to $94.65 (bull), the price of $42.55 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 68/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak: less than 2 % a year.
Fukuda Denshi Co., Ltd. reported revenue of ¥140B in FY2026 versus ¥135B in FY2023, a compound +1.2%/yr. Reported net income was ¥18.8B in FY2026, compounding +2.8%/yr from FY2023.
Key figures
Market cap $1.1B · P/E ratio 10.1 · P/S ratio 1.36 · EPS (TTM) $4.20 · Net margin 13.5% · Return on equity 10.5% · Return on assets (EBIT) 12.0% · Operating margin 14.8%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at 71%, FKDSF screens cheaper than that median.
Fair Value models
Bear $50.97Fair Value $72.81Bull $94.65
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 6 months old). Earnings retained since then ($2.11 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
+0.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.2%
’23
’24
’25
’26
What shareholders gained per year (last 3 years), in JPY ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in JPY: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+4.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year+4.5%
Dividend (yield on the price)0.0%
Profit margin 2023 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.18% → 19%
Growth Forecast
Price in line with expectations
The price assumes about as much growth as the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+1.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (figures in JPY, Japan: IMF forecast 2.1% a year to 2030, 1.3% from 2016 to 2025) that is about −0.3% a year for the price.
Compare Fukuda Denshi Co., Ltd. with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 360 stocks
Beats the industry median on 11/12 measures
Overall it ranks above its industry peers.
Valuation
Quality Score68 · Top 25%
Fair Value upside+71.1% · Top 25%
Profitability
Return on equity (TTM)10.5% · Above median
Return on assets7.7% · Top 25%
Net margin (TTM)13.6% · Above median
Operating margin (TTM)14.8% · Above median
Growth and dividend
Revenue growth2.0% · Below median
Valuation Multiplesvs Medical Devices median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Fukuda Denshi Co., Ltd. (FKDSF) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $72.81 versus a price of $42.55, about +71% upside (undervalued).
What is the fair value of FKDSF?
Our model-based fair value for Fukuda Denshi Co., Ltd. is $72.81 (as of Sep 24, 2026), built from audited fundamentals. The current price: $42.55.
What is the quality score of FKDSF?
Fukuda Denshi Co., Ltd. has a Quality Score of 68/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Fukuda Denshi Co., Ltd. (FKDSF)?
Our model-based price target is the fair value of $72.81 (as of Sep 24, 2026) from 24 valuation models. Cautious scenario $50.97, optimistic scenario $94.65. It is a calculation from audited fundamentals, not an analyst target.
What is the Fukuda Denshi Co., Ltd. stock forecast for 2026?
Our models put fair value at $72.81, about +71% upside versus a price of $42.55 (undervalued). Cautious scenario $50.97, optimistic scenario $94.65. The calculation is refreshed regularly with new filings.
What is the revenue of Fukuda Denshi Co., Ltd. (FKDSF)?
Fukuda Denshi Co., Ltd. reported trailing-twelve-month revenue of about ¥140B (latest available figure, as of Sep 24, 2026).
What growth is priced into Fukuda Denshi Co., Ltd. (FKDSF)?
For today's price to be fair in a discounted-cash-flow model, Fukuda Denshi Co., Ltd. would have to grow free cash flow by +1.8 % per year for five years (discount rate 10.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 3 years revenue grew +1.2 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of FKDSF use?
Our models discount Fukuda Denshi Co., Ltd. at 10.1 %: a base by market capitalisation (small), damped by beta 0.60, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Fukuda Denshi Co., Ltd. that is +1.8 % per year a year over ten years, using the same discount rate (10.1 %) and the same formula as our fair value.
How much growth has Fukuda Denshi Co., Ltd. (FKDSF) delivered so far?
Over the past 3 years revenue at Fukuda Denshi Co., Ltd. grew +1.2 % a year. The price currently implies +1.8 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Fukuda Denshi Co., Ltd. (FKDSF) growing?
The median revenue growth in the sector is +0.0 % a year. That is the yardstick for the growth priced into Fukuda Denshi Co., Ltd. (+1.8 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Fukuda Denshi Co., Ltd. (FKDSF)?
The free-cash-flow yield on the price is 5.21 %: that much free cash flow Fukuda Denshi Co., Ltd. produces per unit of market value. When it exceeds the discount rate of our models (10.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Fukuda Denshi Co., Ltd. (FKDSF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Fukuda Denshi Co., Ltd. it is $72.81 per share (as of Sep 24, 2026), against a price of $42.55. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Fukuda Denshi Co., Ltd. stock overvalued or undervalued in 2026?
As of Sep 24, 2026, FKDSF trades below its calculated fair value: price $42.55, fair value $72.81, a gap of about +71% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of FKDSF?
No. The price is what the market pays today ($42.55); the fair value is what the company's own numbers justify ($72.81). For Fukuda Denshi Co., Ltd. the two are $30.26 per share apart. That gap is exactly why we show both numbers side by side.
How much is Fukuda Denshi Co., Ltd. worth?
The market values Fukuda Denshi Co., Ltd. at about $1.1B (market capitalisation, as of Sep 24, 2026). Per share that is $42.55; our models calculate a fair value of $72.81 per share.
What do the bullish and bearish scenarios say about FKDSF?
Our models span a range for Fukuda Denshi Co., Ltd.: cautious scenario $50.97, base $72.81, optimistic $94.65 per share (as of Sep 24, 2026, price $42.55). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of FKDSF?
Fukuda Denshi Co., Ltd. trades at a price-to-earnings ratio of 10.1 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $72.81 is built from several models across several years. Other multiples: P/B 1.0, P/S 1.3, EV/EBITDA 2.9.
How solid is the balance sheet of Fukuda Denshi Co., Ltd. (FKDSF)?
Balance-sheet figures for Fukuda Denshi Co., Ltd. (as of Sep 24, 2026): return on equity 10.5%. They feed the Quality Score of 68/100, which measures business quality independently of the share price.
Which stocks are comparable to Fukuda Denshi Co., Ltd.?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Fukuda Denshi Co., Ltd. stock attractive at the current price?
The data as of Sep 24, 2026: price $42.55, calculated fair value $72.81 (+71%), Quality Score 68/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of FKDSF calculated?
We run Fukuda Denshi Co., Ltd. through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $72.81, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.9 % above its aggregate fair value. Fukuda Denshi Co., Ltd. currently trades 42 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Fukuda Denshi Co., Ltd. (FKDSF)?
The closing price on Sep 25, 2026 was $42.55. Our model-based fair value is $72.81, about +71% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Fukuda Denshi Co., Ltd. right now?
The price is below even our cautious bear case ($50.97). The market is more pessimistic than our downside scenario. Solid quality (68/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range ($50.97 to $94.65) leaves room in how you read the outcome.
Key figures of Fukuda Denshi Co., Ltd.
How large is the market capitalisation of Fukuda Denshi Co., Ltd. (FKDSF)?
The market capitalisation of Fukuda Denshi Co., Ltd. is $1.1B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Fukuda Denshi Co., Ltd. (FKDSF)?
The price-to-sales ratio of Fukuda Denshi Co., Ltd. is 1.36 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Fukuda Denshi Co., Ltd. (FKDSF)?
Earnings per share at Fukuda Denshi Co., Ltd. are $4.20 (price ÷ EPS = P/E 10.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Fukuda Denshi Co., Ltd. (FKDSF)?
The net margin of Fukuda Denshi Co., Ltd. is 13.5% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Fukuda Denshi Co., Ltd. (FKDSF)?
The return on equity (ROE) of Fukuda Denshi Co., Ltd. is 10.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Fukuda Denshi Co., Ltd. (FKDSF)?
On an EBIT basis the return on assets of Fukuda Denshi Co., Ltd. is 12.0% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Fukuda Denshi Co., Ltd. (FKDSF)?
The operating margin of Fukuda Denshi Co., Ltd. is 14.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Fukuda Denshi Co., Ltd. (FKDSF)?
Revenue at Fukuda Denshi Co., Ltd. is growing +2.0% versus a year earlier (3y avg +1.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Fukuda Denshi Co., Ltd. (FKDSF)?
Earnings per share at Fukuda Denshi Co., Ltd. are growing +13.0% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch Fukuda Denshi Co., Ltd. in the live analysis
One click puts Fukuda Denshi Co., Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Some data
Sep 24, 2026